Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517007 · ClinicalTrials.gov registry record · NA
The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 762
- Enrollment target
NCT03517007: Completed NA study, sponsored by Duke University.
NCT03517007 is a NA study that has completed, run by Duke University. The registered enrollment target is 762 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03517007, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 762 participants
- Enrollment target
Study Summary
The objective of this study is to implement an opt-out protocol to guide appropriate de-escalation of antibiotics in qualifying patients. The protocol, determined over the course a year with the help of a large, well-rounded expert panel, will be used by pharmacists to recommend de-escalation of antibiotics to hospital providers. Providers can then decide whether or not to follow the recommendation in determining the best treatment pathway for his or her patient.
Primary Outcome
Overall inpatient plus post-discharge antibacterial Days of Therapy (DOT) as measured by data collection
Interventions
- OTHER Opt-Out Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2020-08-10 |
| Phase | NA |
What the finished NCT03517007 record still lists
NCT03517007 is an interventional study that assigns participants to a tested intervention. The registered 762 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 1 intervention - of which Opt-Out Protocol is the first listed.
NCT03517007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03517007 about?
NCT03517007 is a clinical study titled "The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial". The objective of this study is to implement an opt-out protocol to guide appropriate de-escalation of antibiotics in qualifying patients. The protocol, determined over the course a year with the help of a large, well-rounded expert panel, will be used by pharmacists to recommend de-escalation of ant...
What is the current status of trial NCT03517007?
This trial is currently completed. It is a NA study. The enrollment target is 762 participants. The study started on 2018-09-12. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT03517007?
The interventions under investigation include: Opt-Out Protocol (OTHER).
Who is sponsoring clinical trial NCT03517007?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03517007's enrollment target sits among peer trials
762 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI